Computational Aided Acetaminophen – Phthalic Acid Molecularly Imprinted Polymer Design for Analytical Determination of Known and New Developed Recreational Drugs

This is a manuscript version of the article.[Abstract] In recent times, abuse drug consumption rates have been increasing. In addition, authorities have detected a trend in the development of new substances expressly created to avoid legislation. These novel psychoactive substances (NPS) are non-registered formulations, closely chemically related to outlawed ones to maintain the same psychotropic effects while circumventing legal restrictions. This issue arises enormous social, sanitary, and road safety problems since there is no way to detect nor quantify these non-registered substances. The aim of this work is the development of a high selective material able to pre-concentrate and detect NPS. On that account, molecularly imprinted polymers (MIPs) designed with an imprinted cavity that matches the cathinones structural shape were proposed to detect both conventional and new cathinone derived recreational drugs. The increasing number of illicit drug modifications that is being reported requires developing a receptor valid for not only known molecules but also for incoming ones; thus, a virtual procedure must be carried out to take a step forward towards future modifications. Accordingly, a computational MIP design is proposed as the most appropriated method to effectively design this receptor. By means of molecular dynamics and molecular docking, several combinations are studied regarding their pre-polymerization complex stability but also their rebinding capacity against the proposed analytes. Hence, a phthalic acid – acetaminophen MIP is selected as the most well-suited receptor, valid for current and forthcoming cathinone recreational drugs.Authors wish to thank Agencia Estatal de Investigación (AEI, Ministerio de Economía y Competitividad) for the financial support through the research project CTQ2016-80473-P cofinanced with FEDER (UE) programm

Selective targeting of collagen IV in the cancer cell microenvironment reduces tumor burden

Goodpasture antigen-binding protein (GPBP) is an exportable1 Ser/Thr kinase that induces collagen IV expansion and has been associated with chemoresistance following epithelial-to-mesenchymal transition (EMT). Here we demonstrate that cancer EMT phenotypes secrete GPBP (mesenchymal GPBP) which displays a predominant multimeric oligomerization and directs the formation of previously unrecognized mesh collagen IV networks (mesenchymal collagen IV). Yeast twohybrid (YTH) system was used to identify a 260SHCIE264 motif critical for multimeric GPBP assembly which then facilitated design of a series of potential peptidomimetics. The compound 3-[4''-methoxy-3,2'-dimethyl-(1,1';4',1'')terphenyl-2''-yl]propionic acid, or T12, specifically targets mesenchymal GPBP and disturbs its multimerization without affecting kinase catalytic site. Importantly, T12 reduces growth and metastases of tumors populated by EMT phenotypes. Moreover, low-dose doxorubicin sensitizes epithelial cancer precursor cells to T12, thereby further reducing tumor load. Given that T12 targets the pathogenic mesenchymal GPBP, it does not bind significantly to normal tissues and therapeutic dosing was not associated with toxicity. T12 is a first-in-class drug candidate to treat cancer by selectively targeting the collagen IV of the tumor cell microenvironment.This work was supported by grants: PET 2006_0721, TRA2009_0026, IPT-010000-2010-45, IPT-2011-1527- 010000, RTC-2014-2415-1, PCB-010000-2010-031, PCB- 010000-2010-032, EQU-2014-1-0301 of the Plan Nacional de Investigación, Desarrollo e Innovación of the Spanish Government and IMGESA/06/78, IMGESA/06/79 of Conselleria d’Empresa, Universitat i Ciencia of Generalitat Valenciana to Fibrostatin, S.L. and J.S.; SAF 2001/0453, SAF 2003-09772-C03-01, SAF 2006-12520-C02-01, SAF 2009-10703 of the Plan Nacional de Investigación, Desarrollo e Innovación of the Spanish Government and PROMETEO/2009/065, PROMETEOII/2014/048 of Conselleria de Educaciò of Generalitat Valenciana to J.S. Additional funding came from ERESA, BioStratum Inc. and NephroGenex Inc. R&D programs, and personal funding from Vicente Saus and Carmen Cano to J.S.. Torres Quevedo program of the Spanish Government granted F.R., F-R-R., R.B., E.L-P and A.P-S.Medicin

Mutations, Genes, and Phenotypes Related to Movement Disorders and Ataxias

26 páginas, 4 figuras, 3 tablasOur clinical series comprises 124 patients with movement disorders (MDs) and/or ataxia with cerebellar atrophy (CA), many of them showing signs of neurodegeneration with brain iron accumulation (NBIA). Ten NBIA genes are accepted, although isolated cases compatible with abnormal brain iron deposits are known. The patients were evaluated using standardised clinical assessments of ataxia and MDs. First, NBIA genes were analysed by Sanger sequencing and 59 patients achieved a diagnosis, including the detection of the founder mutation PANK2 p.T528M in Romani people. Then, we used a custom panel MovDisord and/or exome sequencing; 29 cases were solved with a great genetic heterogeneity (34 different mutations in 23 genes). Three patients presented brain iron deposits with Fe-sensitive MRI sequences and mutations in FBXO7, GLB1, and KIF1A, suggesting an NBIA-like phenotype. Eleven patients showed very early-onset ataxia and CA with cortical hyperintensities caused by mutations in ITPR1, KIF1A, SPTBN2, PLA2G6, PMPCA, and PRDX3. The novel variants were investigated by structural modelling, luciferase analysis, transcript/minigenes studies, or immunofluorescence assays. Our findings expand the phenotypes and the genetics of MDs and ataxias with early-onset CA and cortical hyperintensities and highlight that the abnormal brain iron accumulation or early cerebellar gliosis may resembling an NBIA phenotype.This work was supported by the Instituto de Salud Carlos III (ISCIII)—Subdirección General de Evaluación y Fomento de la Investigación within the framework of the National R + D+I Plan co-funded with European Regional Development Funds (ERDF) [Grants PI18/00147 and PI21/00103 to CE]; the Fundació La Marató TV3 [Grants 20143130 and 20143131 to BPD and CE]; and by the Generalitat Valenciana [Grant PROMETEO/2018/135 to CE]. Part of the equipment employed in this work was funded by Generalitat Valenciana and co-financed with ERDF (OP ERDF of Comunitat Valenciana 2014–2020). PS had an FPU-PhD fellowship funded by the Spanish Ministry of Education, Culture and Sport [FPU15/00964]. IH has a PFIS-PhD fellowship [FI19/00072]. ASM has a contract funded by the Spanish Foundation Per Amor a l’Art (FPAA)Peer reviewe

La renovación de la palabra en el bicentenario de la Argentina : los colores de la mirada lingüística

El libro reúne trabajos en los que se exponen resultados de investigaciones presentadas por investigadores de Argentina, Chile, Brasil, España, Italia y Alemania en el XII Congreso de la Sociedad Argentina de Lingüística (SAL), Bicentenario: la renovación de la palabra, realizado en Mendoza, Argentina, entre el 6 y el 9 de abril de 2010. Las temáticas abordadas en los 167 capítulos muestran las grandes líneas de investigación que se desarrollan fundamentalmente en nuestro país, pero también en los otros países mencionados arriba, y señalan además las áreas que recién se inician, con poca tradición en nuestro país y que deberían fomentarse. Los trabajos aquí publicados se enmarcan dentro de las siguientes disciplinas y/o campos de investigación: Fonología, Sintaxis, Semántica y Pragmática, Lingüística Cognitiva, Análisis del Discurso, Psicolingüística, Adquisición de la Lengua, Sociolingüística y Dialectología, Didáctica de la lengua, Lingüística Aplicada, Lingüística Computacional, Historia de la Lengua y la Lingüística, Lenguas Aborígenes, Filosofía del Lenguaje, Lexicología y Terminología

Molekulare Mechanismen der Thrombin-induzierten ersten und zweiten Phase der ERK1/2-Phosphorylierung in vaskulären glatten Gefäßmuskelzellen

Vascular smooth muscle (VSM) cells are highly specialized cells whose primary function is the contraction of blood vessels and the regulation of vascular tone. Differentiated VSM cells exhibit a low rate of proliferation and a low synthetic activity. Under pathological conditions, VSM cells change from the normal differentiated state to a proliferative, synthetic phenotype. Pathologically altered VSM cells contribute to the progression of vascular diseases. The ERK/MAPK signaling pathway is involved in the phenotypic modulation of several cell types. Various studies have demonstrated that a thrombin-induced redifferentation of VSM cells require a biphasic activation of ERK1/2 via EGFR transactivation. However, the mechanisms of the cessation and delayed reappearance of the ERK1/2 phosphorylation remain elusive. The findings presented here demonstrate the necessity of {\it de novo\/} RNA and protein synthesis for the long-lasting ERK1/2 activation. Inhibition of the second phase of the ERK1/2 phosphorylation by cytochalasin D, or brefeldin A treatment, indicated that the transport of plasma membrane-resident or of secretory proteins may play a critical role in this signalling cascade. Analysis of the thrombin-induced transcription and expression rates of plasma membrane-resident proteins revealed an upregulation of heparin-binding EGF- like growth factor (HB-EGF) with a temporal pattern that closely matches the second phase of ERK1/2 activation. Using confocal laser scanning microscopy, it could be demonstrated that HB-EGF is rapidly processed and transported to the plasma membrane. This result was supported by HB-EGF immunoblot analysis in VSM cell membrane fractions. Inhibition of both phases of ERK1/2 activation by MMP inactivation and blocking of the EGFR autophosphorylation demonstrated the requirement of the extracellular shedding and receptor tyrosine kinase activation for the PAR1-induced ERK1/2 phosphorylation. Pharmacological and RNA interference-mediated modulation of HB-EGF expression abolished the late phase of ERK1/2 phosphorylation, demonstrating that {\it de novo\/} HB-EGF expression and HB-EGF-induced EGFR transactivation are necessary intermediates in the thrombin-induced long-lasting ERK1/2 activation in VSM cells. Future investigations should elucidate the implication of HB-EGF in the redifferentiation of other cell types. Although it is suggested, that Src and Pyk2 contribute to the thrombin-induced ERK1/2 activation, there is a controversy over the role of both proteins in the GPCR-induced ERK1/2 phosphorylation. The results of this work demonstrated that, upon thrombin stimulation, the long-lasting ERK1/2 activation requires Src activation. Moreover, reduction of the first phase of ERK1/2 phosphorylation by MMP inactivation, HB-EGF-scavenging, or blocking of the EGFR autophosphorylation indicated that Src and Pyk2 are downstream effectors of the transactivated EGFR. Surprisingly, analysis of EGFR phosphorylation sites in response to thrombin showed that the Tyr845 of the EGFR was not phosphorylated by Src after EGFR transactivation. Finally, the critical role of Pyk2 in the EGFR- induced Src activation in VSM cells was demonstrated by siRNA-mediated Pyk2 knockdown. Further work will be necessary to elucidate the particular role of Src and Pyk2 in the thrombin-induced ERK1/2 activation.VSM-Zellen sind hochspezialisierte Zellen deren Hauptfunktionen die Kontraktion von Blutgefäßen ist. Unter pathologischen Bedingungen können Gefäßzellen einen Wechsel von einem normalen differenzierten zu einem proliferierenden Zustand vollziehen. Diese Pathologisch veränderten Zellen sind in der Entwicklung kardiovaskulärer Krankheiten beteiligt. Der ERK/MAPK Signalweg ist an der phänotypischen Modulation von verschiedenen Zelltypen beteiligt. Eine Thrombin-induzierte "Re-differenzierung" von VSM-Zellen erfordert eine zweiphasige Aktivierung von ERK1/2. Jedoch ist der Mechanismus des Beginns und des Wiedererscheinens des Differenzierungs-Signalwegs unklar. Die in dieser Arbeit präsentierten Ergebnisse zeigen die Notwendigkeit einer {\it de novo\/} RNA- und Protein-Synthese von HB-EGF für die lang anhaltende Aktivierung von ERK1/2. Eine Inhibierung der zweite Phase einer ERK1/2 Phosphorylierung durch Cytochalasin D oder Brefeldin A Behandlung, weisen daraufhin, dass der Sekretionsprotein-Transport oder der Transport an der Plasmamembran-lokalisierter Proteine eine entscheidende Rolle in der Thrombin- induzierten Signalkaskade spielen. Es konnte gezeigt werden, dass die Stimulation glatter Gefäßmuskelzellen mit Thrombin zu einer erhöhten Transkription und Proteinexpression von HB-EGF führt, die mit der zweiten Phase der ERK1/2 Aktivierung korrelieren. Mittels konfokaler Laser Scanning Mikroskopie wurde ermittelt, dass HB-EGF rasch prozessiert und zu Plasmamembran transportiert wird. Dieses Ergebnis konnte durch eine Immunoblot Analyse von HB-EGF aus VSM-Zell-membranen unterstützt werden. Die Inhibierung beider ERK1/2 Phasen durch MMP-Inaktivierung, und die Blockade der EGFR Autophosphorylierung zeigen, dass die PAR1-induzierte EGFR Transaktivierung den "triple membrane-spanning" Signalweg erfordert. Nach pharmakologischer Modulation von HB-EGF und den Einsatz von HB-EGF-siRNA, konnte gezeigt werden, dass die späte Phase der ERK1/2 Phosphorylierung verhindert wurde und dass die {\it de novo\/} Expression von HB-EGF und dessen induzierte EGFR Transaktivierung notwendige Schritte bei der Thrombin-induzierten Redifferenzierung von VSM-Zellen sind. Weitere Untersuchungen sind notwendig, um den Einfluss von HB-EGF auf die Redifferenzierng anderer Zellen zu verstehen. Obwohl angenommen wird, dass Src und Pyk2 zur ERK1/2 Phosphorylierung beitragen, so sind die Meinungen über ihre Rolle in der GPCR- vermittelten Thrombin-abhängigen ERK1/2 Aktivierung verschieden. Die Ergebnisse dieser Arbeit zeigen, dass eine Stimulation glatter VSM-Zellen mit Thrombin, eine Src Aktivierung benötigt, um ERK1/2 zu phosphorylieren. Da sowohl die Inhibition der MMP Aktivität, als auch die Bindung von HB-EGF durch Heparin oder durch Blockade der EGFR Autophosphorylierung die zweite Phase der ERK1/2 Aktivierung drastisch reduzieren, konnte gezeigt werden, dass Pyk2 und Src nachgeschaltete Effektoren der Transaktivierung des EGFR sind. Untersuchungen der EGFR Phosphorylierung nach Stimulation von glatten Muskelzellen mit Thrombin zeigte, dass das Tyr845 des EGFR nicht durch Src phosphoryliert wird. Schließlich konnte durch Pyk2 Knockout mittels siRNA gezeigt werden, dass Pyk2 ein Zwischenprodukt der EGFR-induzierten Src Aktivierung in VSM-Zellen ist. Untersuchungen müssen vorgenommen werden, um die genaue Rolle von Src und Pyk2 in der Thrombin-induzierten Phosphorylierung von ERK1/2 zu verstehen

EMOOCs 2019: Sixth European MOOCs Stakeholders Summit

Producción CientíficaSince more and more Massive Open Online Courses (MOOCs) appear, constituting an innovative part of online education, they should also undergo quality assurance to assess their pedagogical design similarly to other online courses. Recently, new studies have appeared presenting quality assurance methods (QA) for assessing the instructional design in MOOCs with pedagogical innovations, like those implementing active learning pedagogies (e.g. collaboration, gamification), which provide designers and instructors with useful strategies in order to design more interactive MOOCs. However, it is not that clear how these efforts are being addressed and up to which point are appropriate to assess active learning pedagogies. Therefore, a Systematic Literature Review (SLR) was conducted to identify the most mature existing MOOC QA methods. Afterwards, an evaluative case study was carried out, based on the Evaluand-oriented Responsive Evaluation Model (EREM), to apply the selected methods to a MOOC implementing active learning pedagogies. As the results suggest, the instruments of the selected QA methods need enrichment to assess effectively the instructional design based on active learning pedagogies, by providing specific questions proper for this kind of MOOCs or, by stating the underlying pedagogical model clearly so that the designers could consider beforehand if it is appropriate or not for their case. The results of the study are a first step to define new, enriched quality assessment methods for MOOCs that apply active learning approaches.Ministerio de Ciencia, Innovación y Universidades - Fondo Europeo de Desarrollo Regional (projects TIN2017-85179-C3-2-R / TIN2014-53199-C3-2-R)Junta de Castilla y León - Fondo Europeo de Desarrollo Regional (project VA257P18)Comisión Europea (project 588438-EPP-1-2017-1-EL- EPPKA2-KA

MASK (Mobile Airways Sentinel Network), una app móvil con la solución integral de ARIA en países de habla hispana

Aunque existen guías clínicas de alta calidad sobre rinitis alérgica, numerosos pacientes reciben tratamiento deficiente, en parte debido al alto grado de automedicación. MASK (Mobile Airways Sentinel Network) forma parte integral de un proyecto apoyado por la Unión Europea contra las enfermedades crónicas y enfocado al envejecimiento activo y saludable. Constituye la tercera fase de ARIA (Allergic Rhinitis and its Impact on Asthma), en la cual mediante una aplicación móvil en un dispositivo inteligente se intenta guiar al paciente en el control de su multimorbilidad, rinitis o conjuntivitis alérgicas o asma. La aplicación Diario de Alergia por MACVIA-ARIA es gratuita y está disponible para Android e iOS; en ella, los pacientes indican diariamente cuánto les molestan los síntomas a través de cinco pantallas con una escala visual análoga; recientemente se agregaron dos pantallas más (afectación del sueño). La aplicación también permite descargar los datos del “Diario de alergias” en la computadora del médico en el momento de la consulta a través de un código QR. En este artículo reseñamos el primer año de experiencia en España, México y Argentina, que utilizan la versión española.Fil: Larenas Linnemann, Désirée. Fundación Clínica Médica Sur; ArgentinaFil: Mullol, Joaquim. Universitat de Barcelona; EspañaFil: Ivancevich, Juan Carlos. Clínica Santa Isabel; ArgentinaFil: Anto, Josep M. Universitat Pompeu Fabra; EspañaFil: Cardona, Victoria. Hospital Vall d’Hebron; EspañaFil: Dedeu, Toni. European Regional and Local Health Association; BélgicaFil: Rodríguez González, Mónica. Hospital Español; MéxicoFil: Huerta Villalobos, Yunuen Rocío. Instituto Mexicano del Seguro Social; MéxicoFil: Neffen, Hugo. Center of Allergy; ArgentinaFil: Fuentes Pérez, José Miguel. Instituto Mexicano del Seguro Social; MéxicoFil: Rodríguez Zagal, Endira. Instituto Mexicano del Seguro Social; MéxicoFil: Valero, Antonio. Universidad de Barcelona; EspañaFil: Zernotti, Mario Emilio. Universidad Católica de Córdoba. Facultad de Ciencias de la Salud; ArgentinaFil: Bartra, Joan. Hospital Clínic; EspañaFil: Alobid, Isam. Hospital de La Fe; EspañaFil: Castillo Vizuete, José Antonio. Hospital Universitari Quirón; EspañaFil: Dordal, Teresa. Hospital Municipal Badalona; EspañaFil: Hijano, Rafael. Hospital del Mar; EspañaFil: Picado, César. European Federation of Allergy and Respiratory; España Diseases PatientsFil: Sastre, Joaquín. Fundación Jiménez Díaz; EspañaFil: Blua, Ariel Eduardo. Hospital Privado Universitario de Córdoba; ArgentinaFil: Jares, Edgardo. Sociedad Latinoamericana de Alergia; ArgentinaFil: Lavrut, Alberto Jorge. Hospital General de Niños Pedro de Elizalde; ArgentinaFil: Máspero, Jorge. Fundación Centro de Investigación de Enfermedades Alérgicas y Respiratorias; ArgentinaFil: Bedolla Barajas, Martín. Centro Médico Zambrano Hellion; MéxicoFil: Burguete Cabañas, María Teresa. Hospital Ángeles de Puebla; MéxicoFil: García Cobas, Cecilia Yvonne. Hospital Star Médica Aguascalientes; ArgentinaFil: García Cruz, María de la Luz Hortensia. Hospital Ángeles de Puebla; MéxicoFil: Hernández Velázquez, Luiana. 8Universidad Autónoma de Baja California Campus Ensenada; MéxicoFil: Luna Pech, Jorge A. Universidad de Guadalajara; MéxicoFil: Matta, Juan José. Instituto Mexicano del Seguro Social; MéxicoFil: Mogica Martínez, María Dolores. Instituto Mexicano del Seguro Social; MéxicoFil: Rivero Yeverino, Daniela. Universidad Autónoma de Puebla; ArgentinaFil: Ruiz, Lucy Tania. Instituto Mexicano del Seguro Social; MéxicoFil: Del Río Navarro, Blanca E. Hospital Infantil de México; MéxicoFil: Gómez Vera, Javier. Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado; MéxicoFil: Macías Weinmann, Alejandra. Universidad Autónoma de Nuevo León; MéxicoFil: Murray, Ruth. MedScript Ltd; IrlandaFil: Onorato, Gabrielle. MACVIA-France; FranciaFil: Laune, Daniel. Kyomed; FranciaFil: Bedbrook, Anna. MACVIA-France; FranciaFil: Bousquet, Jean. Université Versailles St-Quentin-en-Yvelines; Franci

MASK (Mobile Airways Sentinel Network). ARIA’s comprehensive solution for mobile app for the multimorbidity of allergic rhinitis and asthma

International audienceThe vast majority of patients with allergic rhinitis (AR) do not receive the proper management which is recommended by the guidelines, but they frequently self-medicate. MASK (Mobile Airways Sentinel Network) is an integral part of a project that is supported by the European Union againstchronic diseases and focused on active and healthy aging. MASK represents the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma), in which, by using a mobile application in a smart device, the objective is to guide the patient in the control of his/her multi-morbidity, AR and/or allergic conjunctivitis (AC) and/or asthma. The mobile app Allergy Diary by MACVIA-ARIA is free and it is available for both Android and iOS platforms. After it is downloaded to the patient’s cell phone, it fi rst requests some information about the patient’s profi le, allergic pathologies and medication; afterwards, through a visual analog scale, the patient is invited to determine the degree of affectation in the nose, eyes, and bronchi, and its influence on their productivity at work / school. After analyzing the data generated by fi lling the Allergy Diary, it became clear there is a new clinical entity: allergic rhinitis+ allergic conjunctivitis +asthma, with greater effect; in addition to a high level of self-medication: in general, the patient takes medication on days when symptoms are present. The app has already been deployed in 23 countries, including several Spanish-speaking countries.La mayor\'ia de los pacientes con rinitis alérgica no recibe el manejo idóneo, sino que se automedica. MASK (Mobile Airways Sentinel Network) forma parte integral de un proyecto apoyado por la Unión Europea contra las enfermedades crónicas y enfocado al envejecimiento activo y saludable. Constituye la tercera fase de ARIA (Allergic Rhinitis and its Impact on Asthma), en la cual mediante una aplicación móvil en un dispositivo inteligente se intenta guiar al paciente en el control de su multimorbilidad, rinitis o conjuntivitis alérgicas o asma. La aplicación Diario de Alergia por MACVIA-ARIA es gratuita y está disponible para Android e iOS. Al descargarla al celular del paciente, a este se le piden datos de su perfil, patolog\'ias alérgicas y medicación; posteriormente, mediante una escala visual analógica se le invita a determinar el grado de afectación en nariz, ojos y bronquios y su influencia sobre su productividad laboral/escolar. Con los datos del Diario de Alergia se observa que existe un nuevo patrón de presentación: rinitis alérgica + conjuntivitis alérgica + asma, con mayor afectación, as\'i como un alto nivel de automedicación: en general, el paciente toma medicación cuando presenta s\'intomas. La app se ha desplegado en 23 pa\'ises, incluyendo varios pa\'ises hispanohablantes

MASK (Mobile Airways Sentinel Network), una app móvil con la solución integral de ARIA en países de habla hispana

Aunque existen guías clínicas de alta calidad sobre rinitis alérgica, numerosos pacientes reciben tratamiento deficiente, en parte debido al alto grado de automedicación. MASK (Mobile Airways Sentinel Network) forma parte integral de un proyecto apoyado por la Unión Europea contra las enfermedades crónicas y enfocado al envejecimiento activo y saludable. Constituye la tercera fase de ARIA (Allergic Rhinitis and its Impact on Asthma), en la cual mediante una aplicación móvil en un dispositivo inteligente se intenta guiar al paciente en el control de su multimorbilidad, rinitis o conjuntivitis alérgicas o asma. La aplicación Diario de Alergia por MACVIA-ARIA es gratuita y está disponible para Android e iOS; en ella, los pacientes indican diariamente cuánto les molestan los síntomas a través de cinco pantallas con una escala visual análoga; recientemente se agregaron dos pantallas más (afectación del sueño). La aplicación también permite descargar los datos del “Diario de alergias” en la computadora del médico en el momento de la consulta a través de un código QR. En este artículo reseñamos el primer año de experiencia en España, México y Argentina, que utilizan la versión española.Although there are high quality clinical guidelines about allergic rhinitis, many patients receive deficient treatment, partly due to the high level of self-medication. MASK (Mobile Airways Sentinel Network) is an integral part of a project against chronic diseases which it is focused on active and healthy aging and is supported by the European Union. It forms the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma) in which, through a mobile app on a smart device, the purpose is to guide patients in the control of their multimorbidity, allergic rhinitis or conjunctivitis, or asthma. The "Allergy Diary" app by MACVIA-ARIA is free and it is available for Android and iOS; on it, patients indicate how unpleasant the symptoms are on a daily basis through five screens with an analogous visual scale; two more screens were recently added (sleep affectation). With the app, it is also possible to download the information of the "Allergy Diary" on the physician's computer through a QR code at the moment of the medical consultation. In this article, we review the first year of experience in Spain, Mexico and Argentina, where the Spanish version is used